InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-49.5%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by Cawkwell Gail, Directeur Exécutif. Director active across 2 companies, notably Intercept Pharmaceuticals, INC.. Aggregated, 12 filings have been logged. History available since 12 May 2021. The latest transaction was disclosed on 12 February 2022 (Retenue fiscale). Regulator: SEC (Form 4). All data is openly available.
Declarations12 total
15,000 sharesCommon StockSEC:0001209191-23-041060:0
320 shares@ US$15.804.3% of flowCommon StockSEC:0001104659-22-023838:0
6,600 shares0Common StockSEC:0001104659-22-009553:0
6,600 shares0Common StockSEC:0001104659-22-009553
2,455 shares@ US$16.2971.4% of flowCommon StockSEC:0001104659-22-000909
2,455 shares@ US$16.2934.2% of flowCommon StockSEC:0001104659-22-000909:0
319 shares@ US$19.045.1% of flowCommon StockSEC:0001104659-21-140028:0
319 shares@ US$19.0410.7% of flowCommon StockSEC:0001104659-21-140028
319 shares@ US$15.284.0% of flowCommon StockSEC:0001104659-21-105301:0
319 shares@ US$15.284.0% of flowCommon StockSEC:0001104659-21-105301
319 shares@ US$17.754.5% of flowCommon StockSEC:0001104659-21-066143
319 shares@ US$17.754.5% of flowCommon StockSEC:0001104659-21-066143:0
12 of 12 declarations
About Cawkwell Gail
Gail Cawkwell is the Executive Vice President of Medical Affairs, Safety & Pharmacovigilance at Intercept Pharmaceuticals, Inc. She is responsible for medical strategy and product safety. Her expertise is essential for ensuring compliance and safety of treatments.
